In lung cancer cell lines with the FGF2/FGFR1 pathway, targeting this resistance mechanism with EGFR-specific TKI does not significantly increase apoptosis, indicating that FGFR inhibitors may stabilize tumor progression rather than cause tumor regression (208). The gene discussed is EGFR; the disease is lung cancer.